{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T03:18:28Z","timestamp":1794367108927,"version":"4.9.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T00:00:00Z","timestamp":1783468800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T00:00:00Z","timestamp":1783468800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"published-print":{"date-parts":[[2026,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Axillary management after neoadjuvant chemotherapy (NAC) in node-positive breast cancer remains controversial. This study assessed the association between total lymph node count, in the context of metastatic lymph node count and lymph node ratio (LNR), and recurrence after NAC in a cohort of young women with node-positive breast cancer.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Retrospective data were analyzed from 274 women aged \u2264\u00a045 years diagnosed with clinical T1\u20133, N1\u20133, M0 invasive breast cancer between January 2010 and December 2023 who received NAC before undergoing surgery at our institution. Primary outcomes were recurrence and overall survival. Total lymph node counts across three LNR tiers were compared between women with at least one metastatic node out of at least three retrieved nodes who did and did not develop recurrence.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Patients who developed a recurrence presented with more advanced clinical T (\n                      <jats:italic>p<\/jats:italic>\n                      \u00a0&lt;\u00a00.001) and N (p\u00a0=\u00a00.01) staging and had greater residual burden of disease in both the breast (\n                      <jats:italic>p\u00a0<\/jats:italic>\n                      &lt;\u00a00.001) and the lymph nodes (\n                      <jats:italic>p<\/jats:italic>\n                      \u00a0&lt;\u00a00.001) than did patients with no recurrence. There was no significant correlation between total number of lymph nodes excised and recurrence in women with at least one metastatic node out of at least three examined nodes in any of the low (\n                      <jats:italic>p<\/jats:italic>\n                      \u00a0=\u00a00.39), intermediate (\n                      <jats:italic>p<\/jats:italic>\n                      \u00a0=\u00a00.47), or high (\n                      <jats:italic>p<\/jats:italic>\n                      \u00a0=\u00a00.67) LNR tiers.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Tumor biology, chemoresistance, and residual tumor burden after NAC may influence oncologic outcomes more than the number of nodes removed or the extent of nodal surgery. Prospective, large-scale, long-term studies are needed to rigorously address this question, particularly in this young, high-risk population.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1245\/s10434-026-20154-w","type":"journal-article","created":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T16:18:01Z","timestamp":1783527481000},"page":"9888-9895","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Impact of Total and Positive Lymph Node Count on Recurrence in Young Women with Node-Positive Breast Cancer Undergoing Neoadjuvant Chemotherapy"],"prefix":"10.1245","volume":"33","author":[{"given":"Lucy","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shama","family":"Birla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophia X.","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivia W.","family":"Galloway","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sydney","family":"Kinkade","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ariana","family":"Naaseh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omolade O.","family":"Sogade","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie A.","family":"Margenthaler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,8]]},"reference":[{"issue":"9","key":"20154_CR1","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1056\/NEJMoa1910549","volume":"382","author":"P Schmid","year":"2020","unstructured":"Schmid P, Cortes J, Pusztai L, et al. Pembrolizumab for early triple-negative breast cancer. N Engl J Med. 2020;382(9):810\u201321. https:\/\/doi.org\/10.1056\/NEJMoa1910549.","journal-title":"N Engl J Med."},{"key":"20154_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/j.breast.2026.104765","volume":"87","author":"C Corti","year":"2026","unstructured":"Corti C, Li T, Martin AR, et al. Impact of pathologic response and individual prognosis after neoadjuvant treatment in patients with early HER2+ and triple-negative breast cancer. Breast. 2026;87:104765. https:\/\/doi.org\/10.1016\/j.breast.2026.104765.","journal-title":"Breast."},{"key":"20154_CR3","unstructured":"NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae) for Breast Cancer V.2.2026. National Comprehensive Cancer Network. Accessed April 9, 2026, https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/breast.pdf"},{"issue":"4","key":"20154_CR4","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1097\/SLA.0000000000001375","volume":"263","author":"JC Boughey","year":"2016","unstructured":"Boughey JC, Ballman KV, Le-Petross HT, et al. Identification and resection of clipped node decreases the false-negative rate of sentinel lymph node surgery in patients presenting with node-positive breast cancer (T0\u2013T4, N1\u2013N2) who receive neoadjuvant chemotherapy: results from ACOSOG Z1071 (alliance). Ann Surg. 2016;263(4):802\u20137. https:\/\/doi.org\/10.1097\/SLA.0000000000001375.","journal-title":"Ann Surg."},{"issue":"14","key":"20154_CR5","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.1001\/jama.2013.278932","volume":"310","author":"JC Boughey","year":"2013","unstructured":"Boughey JC, Suman VJ, Mittendorf EA, et al. Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with node-positive breast cancer: the ACOSOG Z1071 (alliance) clinical trial. JAMA. 2013;310(14):1455\u201361. https:\/\/doi.org\/10.1001\/jama.2013.278932.","journal-title":"JAMA."},{"issue":"7","key":"20154_CR6","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1016\/S1470-2045(13)70166-9","volume":"14","author":"T Kuehn","year":"2013","unstructured":"Kuehn T, Bauerfeind I, Fehm T, et al. Sentinel-lymph-node biopsy in patients with breast cancer before and after neoadjuvant chemotherapy (SENTINA): a prospective, multicentre cohort study. Lancet Oncol. 2013;14(7):609\u201318. https:\/\/doi.org\/10.1016\/S1470-2045(13)70166-9.","journal-title":"Lancet Oncol."},{"issue":"3","key":"20154_CR7","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1200\/JCO.2014.55.7827","volume":"33","author":"JF Boileau","year":"2015","unstructured":"Boileau JF, Poirier B, Basik M, et al. Sentinel node biopsy after neoadjuvant chemotherapy in biopsy-proven node-positive breast cancer: the SN FNAC study. J Clin Oncol. 2015;33(3):258\u201364. https:\/\/doi.org\/10.1200\/JCO.2014.55.7827.","journal-title":"J Clin Oncol."},{"issue":"5","key":"20154_CR8","doi-asserted-by":"publisher","first-page":"3278","DOI":"10.1245\/s10434-025-16973-y","volume":"32","author":"JC Boughey","year":"2025","unstructured":"Boughey JC, Yu H, Switalla K, et al. Oncologic outcomes with de-escalation of axillary surgery after neoadjuvant chemotherapy for breast cancer: results from > 1500 patients on the I-SPY2 clinical trial. Ann Surg Oncol. 2025;32(5):3278\u201391. https:\/\/doi.org\/10.1245\/s10434-025-16973-y.","journal-title":"Ann Surg Oncol."},{"issue":"1","key":"20154_CR9","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/S1470-2045(25)00598-4","volume":"27","author":"G Montagna","year":"2026","unstructured":"Montagna G, Alvarado M, Myers S, et al. Oncological outcomes with and without axillary lymph node dissection in patients with residual micrometastases after neoadjuvant chemotherapy (OPBC-07\/microNAC): an international, retrospective cohort study. Lancet Oncol. 2026;27(1):57\u201367. https:\/\/doi.org\/10.1016\/S1470-2045(25)00598-4.","journal-title":"Lancet Oncol."},{"issue":"27","key":"20154_CR10","doi-asserted-by":"publisher","first-page":"3308","DOI":"10.1200\/JCO.2015.65.8013","volume":"34","author":"AH Partridge","year":"2016","unstructured":"Partridge AH, Hughes ME, Warner ET, et al. Subtype-dependent relationship between young age at diagnosis and breast cancer survival. J Clin Oncol. 2016;34(27):3308\u201314. https:\/\/doi.org\/10.1200\/JCO.2015.65.8013.","journal-title":"J Clin Oncol."},{"issue":"1","key":"20154_CR11","doi-asserted-by":"publisher","first-page":"5655","DOI":"10.1038\/s41598-025-90053-9","volume":"15","author":"ROC Humlevik","year":"2025","unstructured":"Humlevik ROC, Svan\u00f8e AA, Aas T, et al. Distinct clinicopathological features and treatment differences in breast cancer patients of young age. Sci Rep. 2025;15(1):5655. https:\/\/doi.org\/10.1038\/s41598-025-90053-9.","journal-title":"Sci Rep."},{"issue":"1","key":"20154_CR12","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1007\/s10549-020-06000-x","volume":"186","author":"X Hu","year":"2021","unstructured":"Hu X, Myers KS, Oluyemi ET, Philip M, Azizi A, Ambinder EB. Presentation and characteristics of breast cancer in young women under age 40. Breast Cancer Res Treat. 2021;186(1):209\u201317. https:\/\/doi.org\/10.1007\/s10549-020-06000-x.","journal-title":"Breast Cancer Res Treat."},{"issue":"4","key":"20154_CR13","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1177\/00031348231209532","volume":"90","author":"S Ichhpuniani","year":"2024","unstructured":"Ichhpuniani S, McKechnie T, Lee J, et al. Lymph node ratio as a predictor of survival for colon cancer: a systematic review and meta-analysis. Am Surg. 2024;90(4):840\u201350. https:\/\/doi.org\/10.1177\/00031348231209532.","journal-title":"Am Surg."},{"issue":"5","key":"20154_CR14","doi-asserted-by":"publisher","first-page":"1614","DOI":"10.1016\/j.athoracsur.2012.01.065","volume":"93","author":"CE Nwogu","year":"2012","unstructured":"Nwogu CE, Groman A, Fahey D, et al. Number of lymph nodes and metastatic lymph node ratio are associated with survival in lung cancer. Ann Thorac Surg. 2012;93(5):1614\u20139.","journal-title":"Ann Thorac Surg."},{"issue":"5","key":"20154_CR15","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1016\/j.surg.2006.12.013","volume":"141","author":"TM Pawlik","year":"2007","unstructured":"Pawlik TM, Gleisner AL, Cameron JL, et al. Prognostic relevance of lymph node ratio following pancreaticoduodenectomy for pancreatic cancer. Surgery. 2007;141(5):610\u20138. https:\/\/doi.org\/10.1016\/j.surg.2006.12.013.","journal-title":"Surgery."},{"issue":"10","key":"20154_CR16","doi-asserted-by":"publisher","first-page":"3310","DOI":"10.1245\/s10434-016-5319-8","volume":"23","author":"J Tsai","year":"2016","unstructured":"Tsai J, Bertoni D, Hernandez-Boussard T, Telli ML, Wapnir IL. Lymph node ratio analysis after neoadjuvant chemotherapy is prognostic in hormone receptor-positive and triple-negative breast cancer. Ann Surg Oncol. 2016;23(10):3310\u20136. https:\/\/doi.org\/10.1245\/s10434-016-5319-8.","journal-title":"Ann Surg Oncol."},{"issue":"4","key":"20154_CR17","doi-asserted-by":"publisher","first-page":"249","DOI":"10.5152\/ejbh.2019.4848","volume":"15","author":"A Soran","year":"2019","unstructured":"Soran A, Ozmen T, Salamat A, Soybir G, Johnson R. Lymph node ratio (LNR): predicting prognosis after neoadjuvant chemotherapy (NAC) in breast cancer patients. Eur J Breast Health. 2019;15(4):249\u201355. https:\/\/doi.org\/10.5152\/ejbh.2019.4848.","journal-title":"Eur J Breast Health."},{"issue":"2","key":"20154_CR18","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1245\/s10434-022-12605-x","volume":"30","author":"T Schwartz","year":"2023","unstructured":"Schwartz T, Marumoto AD, Giuliano AE. Surgical management of the axilla in breast cancer: evolving but still necessary. Ann Surg Oncol. 2023;30(2):1008\u201313. https:\/\/doi.org\/10.1245\/s10434-022-12605-x.","journal-title":"Ann Surg Oncol."},{"issue":"4","key":"20154_CR19","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1097\/SLA.0000000000000924","volume":"260","author":"JC Boughey","year":"2014","unstructured":"Boughey JC, McCall LM, Ballman KV, et al. Tumor biology correlates with rates of breast-conserving surgery and pathologic complete response after neoadjuvant chemotherapy for breast cancer: findings from the ACOSOG Z1071 (alliance) prospective multicenter clinical trial. Ann Surg. 2014;260(4):608\u201314.","journal-title":"Ann Surg"},{"issue":"34","key":"20154_CR20","doi-asserted-by":"publisher","first-page":"3987","DOI":"10.1200\/JCO.20.02514","volume":"38","author":"SRD Johnston","year":"2020","unstructured":"Johnston SRD, Harbeck N, Hegg R, et al. Abemaciclib combined with endocrine therapy for the adjuvant treatment of HR+, HER2-, node-positive, High-Risk, early breast cancer (monarchE). J Clin Oncol. 2020;38(34):3987\u201398. https:\/\/doi.org\/10.1200\/JCO.20.02514.","journal-title":"J Clin Oncol."},{"issue":"1","key":"20154_CR21","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1097\/XCS.0000000000000714","volume":"237","author":"B Vuong","year":"2023","unstructured":"Vuong B, Darbinian J, Savitz A, et al. Breast cancer recurrence by subtype in a diverse, contemporary cohort of young women. J Am Coll Surg. 2023;237(1):13\u201323. https:\/\/doi.org\/10.1097\/XCS.0000000000000714.","journal-title":"J Am Coll Surg."},{"issue":"6","key":"20154_CR22","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1001\/jamaoncol.2025.0178","volume":"11","author":"Y Abdou","year":"2025","unstructured":"Abdou Y, Kantor O, Racz J, Newman L, Pierce LJ, Winer EP. Prognostic and predictive insights from genomic assays for breast cancer in diverse populations: a review. JAMA Oncol. 2025;11(6):655\u201363. https:\/\/doi.org\/10.1001\/jamaoncol.2025.0178.","journal-title":"JAMA Oncol."},{"key":"20154_CR23","unstructured":"NCT01901094: Comparison of Axillary Lymph Node Dissection with Axillary Radiation for Patients with Node-Positive Breast Cancer Treated with Chemotherapy. ClinicalTrials.gov. https:\/\/clinicaltrials.gov\/study\/NCT01901094"},{"issue":"4","key":"20154_CR24","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1038\/s41571-026-01120-7","volume":"23","author":"S Lobo-Martins","year":"2026","unstructured":"Lobo-Martins S, Luen SJ, Piccart M, Loi S. Tailoring targeted therapies for younger women with ER-positive early-stage breast cancer. Nat Rev Clin Oncol. 2026;23(4):297\u2013315. https:\/\/doi.org\/10.1038\/s41571-026-01120-7.","journal-title":"Nat Rev Clin Oncol."},{"issue":"1","key":"20154_CR25","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1007\/s12609-025-00578-1","volume":"17","author":"JS Olapo","year":"2025","unstructured":"Olapo JS, Brennan SK, Javid SH, Flanagan MR. Neoadjuvant systemic therapy versus up-front surgery in ER+\/PR+\/HER2- breast cancer. Curr Breast Cancer Rep. 2025;17(1):19. https:\/\/doi.org\/10.1007\/s12609-025-00578-1.","journal-title":"Curr Breast Cancer Rep."},{"issue":"25","key":"20154_CR26","doi-asserted-by":"publisher","first-page":"2336","DOI":"10.1056\/NEJMoa2108873","volume":"385","author":"K Kalinsky","year":"2021","unstructured":"Kalinsky K, Barlow WE, Gralow JR, et al. 21-gene assay to inform chemotherapy benefit in node-positive breast cancer. N Engl J Med. 2021;385(25):2336\u201347. https:\/\/doi.org\/10.1056\/NEJMoa2108873.","journal-title":"N Engl J Med."},{"issue":"16","key":"20154_CR27","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1200\/JCO.2026.44.16_suppl.500","volume":"44","author":"RC Stein","year":"2026","unstructured":"Stein RC, Makris A, Macpherson IR, et al. First results from the OPTIMA phase III randomized non-inferiority trial of test-directed chemotherapy in patients with high clinical risk ER-positive HER2-negative early breast cancer. J Clin Oncol. 2026;44(16):500\u2013500. https:\/\/doi.org\/10.1200\/JCO.2026.44.16_suppl.500.","journal-title":"J Clin Oncol."},{"key":"20154_CR28","unstructured":"NCT05879926: Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive\/\u200bHER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25 (OFSET). ClinicalTrials.gov."}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-026-20154-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1245\/s10434-026-20154-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-026-20154-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T15:17:52Z","timestamp":1790867872000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1245\/s10434-026-20154-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,8]]},"references-count":28,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["20154"],"URL":"https:\/\/doi.org\/10.1245\/s10434-026-20154-w","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"value":"1068-9265","type":"print"},{"value":"1534-4681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,8]]},"assertion":[{"value":"27 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors report no conflicts of interest.","order":1,"name":"Ethics","label":"Disclosure","group":{"name":"EthicsHeading","label":"Ethics"}}]}}